Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, Yoda S, Satomi R, Naoki K, Betsuyaku T.
Terai H, et al. Among authors: yasuda h.
Mol Cancer Res. 2013 Jul;11(7):759-67. doi: 10.1158/1541-7786.MCR-12-0652. Epub 2013 Mar 27.
Mol Cancer Res. 2013.
PMID: 23536707
Free article.